Integrative Analysis of Siglec-15 MRNA in Human Cancers Based on Data Mining

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Mar 24

PMID 32201516

Citations 22

Authors

Qiu-Ting Li

Zao-Zao Huang

Yao-Bin Chen

Hong-Yi Yao

Zun-Hui Ke

Xiao-Xiao He

Meng-Jun Qiu

Meng-Meng Wang

Zhi-Fan Xiong

Sheng-li Yang

Affiliations

Soon will be listed here.

Abstract

: Cancer is expected to be the leading cause of death worldwide within the 21st century and is the single most important obstacle to extending life expectancy. Unfortunately, the most effective approach to combating cancers remains a complex and unsolved problem. Siglec-15 is a member of the Siglec family and plays a conserved regulatory role in the immune system of vertebrates. Previous studies on Siglec-15 have focused on its function in osteoclast regulation. The purpose of this study was to explore the significance of Siglec-15 mRNA in human cancer mainly based on information obtained from online databases. : Data were collected from several online databases. Serial analysis of gene expression (SAGE) and Virtual Northern, UALCAN Database Analysis, Catalog of Somatic Mutations in Cancer (COSMIC) analysis, the cBio cancer genomics portal, Cancer Regulome tools and data, Kaplan-Meier Plotter Analysis and the UCSC Xena website were used to analyze the data. : Compared with normal tissues, Siglec-15 up-regulation was widely observed in tuomrs. Differences in Siglec-15 expression were associated with different prognoses. Siglec-15 mutations are widely observed in tumors and interact with different genes in different cancer types. : Siglec-15 is a potential target for the expansion of cancer immunotherapy.

Citing Articles

Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer.

Chu C, Fu Y, Yang J, Fan X, Shi J Front Oncol. 2025; 14:1437006.

PMID: 39743995 PMC: 11688221. DOI: 10.3389/fonc.2024.1437006.

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.

Feng H, Feng J, Han X, Ying Y, Lou W, Liu L Cancers (Basel). 2024; 16(2).

PMID: 38254780 PMC: 10813689. DOI: 10.3390/cancers16020289.

Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.

Wang Y, Xu Z, Wu K, Yu L, Wang C, Ding H Proc Natl Acad Sci U S A. 2024; 121(5):e2312929121.

PMID: 38252825 PMC: 10835054. DOI: 10.1073/pnas.2312929121.

Incorporating mutational heterogeneity to identify genes that are enriched for synonymous mutations in cancer.

Rao Y, Ahmed N, Pritchard J, OBrien E BMC Bioinformatics. 2023; 24(1):462.

PMID: 38062391 PMC: 10704839. DOI: 10.1186/s12859-023-05521-8.

The expression of two immunosuppressive SIGLEC family molecules in papillary thyroid cancer and their effect on prognosis.

Jin T, Wang W, Ge L, Li X, Ge M Endocrine. 2023; 82(3):590-601.

PMID: 37480496 DOI: 10.1007/s12020-023-03452-1.

References

Madge P, Maggioni A, Pascolutti M, Amin M, Waespy M, Bellette B . Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy. Sci Rep. 2016; 6:36012. PMC: 5093622. DOI: 10.1038/srep36012. View

Angata T, Tabuchi Y, Nakamura K, Nakamura M . Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology. 2007; 17(8):838-46. DOI: 10.1093/glycob/cwm049. View

Chen T, Triplett J, Dehner B, Hurst B, Colligan B, Pemberton J . Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res. 2001; 61(12):4679-82. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

Adams O, Stanczak M, von Gunten S, Laubli H . Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology. 2018; 28(9):640-647. DOI: 10.1093/glycob/cwx108. View

Passiglia F, Galvano A, Rizzo S, Incorvaia L, Listi A, Bazan V . Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer. 2017; 142(6):1277-1284. DOI: 10.1002/ijc.31136. View

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Kameda Y, Takahata M, Komatsu M, Mikuni S, Hatakeyama S, Shimizu T . Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12. J Bone Miner Res. 2013; 28(12):2463-75. DOI: 10.1002/jbmr.1989. View

11.

Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T . The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology. 2012; 23(2):178-87. DOI: 10.1093/glycob/cws139. View

12.

Schauer R . Achievements and challenges of sialic acid research. Glycoconj J. 2001; 17(7-9):485-99. PMC: 7087979. DOI: 10.1023/a:1011062223612. View

13.

Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka S . Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocr Relat Cancer. 2004; 11(4):843-54. DOI: 10.1677/erc.1.00818. View

14.

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

15.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J . Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268(5215):1336-8. DOI: 10.1126/science.7761852. View

16.

Stuible M, Moraitis A, Fortin A, Saragosa S, Kalbakji A, Filion M . Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption. J Biol Chem. 2014; 289(10):6498-6512. PMC: 3945315. DOI: 10.1074/jbc.M113.494542. View

17.

Wang Q, Chen X, Hay N . Akt as a target for cancer therapy: more is not always better (lessons from studies in mice). Br J Cancer. 2017; 117(2):159-163. PMC: 5520506. DOI: 10.1038/bjc.2017.153. View

18.

Kaczorowski M, Biecek P, Donizy P, Pieniazek M, Matkowski R, Halon A . SMAD7 is a novel independent predictor of survival in patients with cutaneous melanoma. Transl Res. 2018; 204:72-81. DOI: 10.1016/j.trsl.2018.09.002. View

19.

Ren X . Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. Cancer Biol Med. 2019; 16(2):205-210. PMC: 6713637. DOI: 10.20892/j.issn.2095-3941.2018.0141. View

20.

Silva A, de Souza J, Galante P, Riggins G, de Souza S, Camargo A . The impact of SNPs on the interpretation of SAGE and MPSS experimental data. Nucleic Acids Res. 2004; 32(20):6104-10. PMC: 534621. DOI: 10.1093/nar/gkh937. View